Skip to main
NVO
NVO logo

Novo Nordisk (NVO) Stock Forecast & Price Target

Novo Nordisk (NVO) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 38%
Hold 38%
Sell 0%
Strong Sell 0%

Bulls say

Novo Nordisk commands a significant presence in the global branded diabetes treatment market, holding approximately one third of the market share. The company is poised for growth, particularly in its GLP-1 franchise, which is projected to experience 25% higher growth, bolstered by anticipated regulatory approvals and a positive Phase 3 trial outcome for semaglutide. Furthermore, improvements in operating expense leverage throughout 2024 are expected to enhance the company's valuation metrics, establishing a favorable outlook for financial performance going forward.

Bears say

Novo Nordisk's growth outlook has been downgraded, with anticipated sales growth in DKK expected to be one percentage point lower than previously anticipated, and operating profit projections reduced by two percentage points. Furthermore, negative outcomes for semaglutide and disappointing Phase 3 data for CagriSema have led to a significant reduction in revenue estimates for these products, as well as a potential decrease in the company's forward P/E multiple to 22x. Compounding these challenges are industry-wide pricing pressures and the risk of unmet revenue expectations, alongside concerns over the stability of key patents that could impact the company's competitive position in the diabetes treatment market.

Novo Nordisk (NVO) has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 38% recommend Buy, 38% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Novo Nordisk and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Novo Nordisk (NVO) Forecast

Analysts have given Novo Nordisk (NVO) a Buy based on their latest research and market trends.

According to 8 analysts, Novo Nordisk (NVO) has a Buy consensus rating as of Jul 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $171.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $171.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Novo Nordisk (NVO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.